

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3138749

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SVEN MENSING	11/21/2014
RECEIVING PARTY DATA		
Name:	ABBVIE DEUTSCHLAND GMBH & CO. KG	
Street Address:	MAX-PLANCK-RING 2A	
City:	WIESBADEN	
State/Country:	GERMANY	
Postal Code:	65205	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	14503849	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	christine.wipper@abbvie.com	
Correspondent Name:	XU ZHANG	
Address Line 1:	1 NORTH WAUKEGAN ROAD	
Address Line 4:	NORTH CHICAGO, ILLINOIS 60064	
ATTORNEY DOCKET NUMBER:	11298USC4	
NAME OF SUBMITTER:	XU ZHANG	
SIGNATURE:	/Xu Zhang/	
DATE SIGNED:	12/09/2014	
Total Attachments: 2		
source=2014_12_08_11298USC4_Assignment_DE_Inventor#page1.tif		
source=2014_12_08_11298USC4_Assignment_DE_Inventor#page2.tif		

ASSIGNMENT

WHEREAS, Sven Mensing of Ilvesheim, Germany hereinafter called the "Assignor", have made the invention described in the United States patent application entitled "Methods for Treating HCV" that has a U.S. Patent Application Serial Number of 13/656,024 and was filed on October 19, 2012;


WHEREAS, AbbVie Deutschland GmbH & Co. KG, a corporation, having a place of business at Max-Planck-Ring 2a, Wiesbaden, Germany 65205, hereinafter called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and to the patent application identified above, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents does sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States and elsewhere; together with the entire right, title and interest in and to said invention and all patent applications, patents, utility models and designs therefor in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications, patents, utility models and designs defined above; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignor hereby covenants and agrees, for both the Assignor and the Assignor's legal representative, that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the invention identified above, in vesting in the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors have executed this agreement.


Sven Mensing

21-Nov 2014
Date